These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 31144591)

  • 1. SPARED Collaboration: Patient Selection for Partial Gland Ablation in Men with Localized Prostate Cancer.
    Gross MD; Sedrakyan A; Bianco FJ; Carroll PR; Daskivich TJ; Eggener SE; Ehdaie B; Fisher B; Gorin MA; Hunt B; Jiang H; Klein EA; Marinac-Dabic D; Montgomery JS; Polascik TJ; Priester AM; Rastinehad AR; Viviano CJ; Wysock JS; Hu JC
    J Urol; 2019 Nov; 202(5):952-958. PubMed ID: 31144591
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of a Nationally Representative Coordinated Registry Network for Prostate Ablation Technologies.
    Golan R; Bernstein A; Sedrakyan A; Daskivich TJ; Du DT; Ehdaie B; Fisher B; Gorin MA; Grunberger I; Hunt B; Jiang HH; Kim HL; Marinac-Dabic D; Marks LS; McClure TD; Montgomery JS; Parekh DJ; Punnen S; Scionti S; Viviano CJ; Wei JT; Wenske S; Wysock JS; Rewcastle J; Carol M; Oczachowski M; Hu JC
    J Urol; 2018 Jun; 199(6):1488-1493. PubMed ID: 29307684
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative Analysis of Partial Gland Ablation and Radical Prostatectomy to Treat Low and Intermediate Risk Prostate Cancer: Oncologic and Functional Outcomes.
    Garcia-Barreras S; Sanchez-Salas R; Sivaraman A; Barret E; Secin F; Nunes-Silva I; Linares-Espinós E; Rozet F; Galiano M; Cathelineau X
    J Urol; 2018 Jan; 199(1):140-146. PubMed ID: 28823768
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Partial Gland Ablation for Prostate Cancer: Report of a Food and Drug Administration, American Urological Association, and Society of Urologic Oncology Public Workshop.
    Jarow JP; Ahmed HU; Choyke PL; Taneja SS; Scardino PT
    Urology; 2016 Feb; 88():8-13. PubMed ID: 26621480
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pilot Study to Assess Safety and Clinical Outcomes of Irreversible Electroporation for Partial Gland Ablation in Men with Prostate Cancer.
    Murray KS; Ehdaie B; Musser J; Mashni J; Srimathveeravalli G; Durack JC; Solomon SB; Coleman JA
    J Urol; 2016 Sep; 196(3):883-90. PubMed ID: 27113966
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Validation of the current eligibility criteria for focal therapy in men with localized prostate cancer and the role of MRI.
    Pompe RS; Kühn-Thomä B; Nagaraj Y; Veleva V; Preisser F; Leyh-Bannurah SR; Graefen M; Huland H; Tilki D; Salomon G
    World J Urol; 2018 May; 36(5):705-712. PubMed ID: 29492583
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Magnetic Resonance Imaging-Guided Transurethral Ultrasound Ablation of Prostate Tissue in Patients with Localized Prostate Cancer: A Prospective Phase 1 Clinical Trial.
    Chin JL; Billia M; Relle J; Roethke MC; Popeneciu IV; Kuru TH; Hatiboglu G; Mueller-Wolf MB; Motsch J; Romagnoli C; Kassam Z; Harle CC; Hafron J; Nandalur KR; Chronik BA; Burtnyk M; Schlemmer HP; Pahernik S
    Eur Urol; 2016 Sep; 70(3):447-55. PubMed ID: 26777228
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Standardized Nomenclature and Surveillance Methodologies After Focal Therapy and Partial Gland Ablation for Localized Prostate Cancer: An International Multidisciplinary Consensus.
    Lebastchi AH; George AK; Polascik TJ; Coleman J; de la Rosette J; Turkbey B; Wood BJ; Gorin MA; Sidana A; Ghai S; Tay KJ; Ward JF; Sanchez-Salas R; Muller BG; Malavaud B; Mozer P; Crouzet S; Choyke PL; Ukimura O; Rastinehad AR; Pinto PA
    Eur Urol; 2020 Sep; 78(3):371-378. PubMed ID: 32532513
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Propensity Score-Matched Comparison of Partial to Whole-Gland Cryotherapy for Intermediate-Risk Prostate Cancer: An Analysis of the Cryo On-Line Data Registry Data.
    Tay KJ; Polascik TJ; Elshafei A; Tsivian E; Jones JS
    J Endourol; 2017 Jun; 31(6):564-571. PubMed ID: 28385075
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New advances in focal therapy for early stage prostate cancer.
    Tay KJ; Schulman AA; Sze C; Tsivian E; Polascik TJ
    Expert Rev Anticancer Ther; 2017 Aug; 17(8):737-743. PubMed ID: 28635336
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Whole gland primary prostate cryoablation: initial results from the cryo on-line data registry.
    Jones JS; Rewcastle JC; Donnelly BJ; Lugnani FM; Pisters LL; Katz AE
    J Urol; 2008 Aug; 180(2):554-8. PubMed ID: 18550117
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Focal Laser Ablation of Prostate Cancer: Phase I Clinical Trial.
    Natarajan S; Raman S; Priester AM; Garritano J; Margolis DJ; Lieu P; Macairan ML; Huang J; Grundfest W; Marks LS
    J Urol; 2016 Jul; 196(1):68-75. PubMed ID: 26748164
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Partial gland ablation in the management of prostate cancer: a review.
    McClure TD; Margolis DJ; Hu JC
    Curr Opin Urol; 2017 Mar; 27(2):156-160. PubMed ID: 28033149
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Candidate selection for quadrant-based focal ablation through a combination of diffusion-weighted magnetic resonance imaging and prostate biopsy.
    Matsuoka Y; Numao N; Saito K; Tanaka H; Kumagai J; Yoshida S; Ishioka J; Koga F; Masuda H; Kawakami S; Fujii Y; Kihara K
    BJU Int; 2016 Jan; 117(1):94-101. PubMed ID: 25124332
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II Evaluation of Magnetic Resonance Imaging Guided Focal Laser Ablation of Prostate Cancer.
    Eggener SE; Yousuf A; Watson S; Wang S; Oto A
    J Urol; 2016 Dec; 196(6):1670-1675. PubMed ID: 27449263
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Need for Systematic Magnetic Resonance Imaging Interpretation and Reporting after Partial Prostate Gland Ablation.
    Hu JC; Basourakos SP; Futterer J
    Eur Urol; 2021 Feb; 79(2):167-169. PubMed ID: 33221091
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Focal Ablation of Early-Stage Prostate Cancer: Candidate Selection, Treatment Guidance, and Assessment of Outcome.
    Edison E; Tariq Shah T; Ahmed HU
    Urol Clin North Am; 2017 Nov; 44(4):575-585. PubMed ID: 29107274
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The safety and efficacy of irreversible electroporation for the ablation of prostate cancer: a multicentre prospective human in vivo pilot study protocol.
    van den Bos W; de Bruin DM; Muller BG; Varkarakis IM; Karagiannis AA; Zondervan PJ; Laguna Pes MP; Veelo DP; Savci Heijink CD; Engelbrecht MRW; Wijkstra H; de Reijke TM; de la Rosette JJMCH
    BMJ Open; 2014 Oct; 4(10):e006382. PubMed ID: 25354827
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pathological Findings and Magnetic Resonance Imaging Concordance at Salvage Radical Prostatectomy for Local Recurrence following Partial Ablation Using High Intensity Focused Ultrasound.
    Thompson JE; Sridhar AN; Tan WS; Freeman A; Haider A; Allen C; Moore CM; Orczyk C; Mazzon G; Khetrapal P; Shaw G; Rajan P; Mohammed A; Briggs TP; Nathan S; Kelly JD; Sooriakumaran P
    J Urol; 2019 Jun; 201(6):1134-1143. PubMed ID: 30730409
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Histopathological Outcomes after Irreversible Electroporation for Prostate Cancer: Results of an Ablate and Resect Study.
    van den Bos W; Jurhill RR; de Bruin DM; Savci-Heijink CD; Postema AW; Wagstaff PG; Muller BG; Varkarakis IM; Skolarikos A; Zondervan PJ; Laguna Pes MP; de Reijke TM; de la Rosette JJ
    J Urol; 2016 Aug; 196(2):552-9. PubMed ID: 27004693
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.